FUNGIZONE POWDER FOR SOLUTION
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
12-12-2019
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
AMPHOTERICIN B
Available from:
CHEPLAPHARM ARZNEIMITTEL GMBH
ATC code:
J02AA01
INN (International Name):
AMPHOTERICIN B
Dosage:
50MG
Pharmaceutical form:
POWDER FOR SOLUTION
Composition:
AMPHOTERICIN B 50MG
Administration route:
INTRAVENOUS
Units in package:
15G/50G
Prescription type:
Prescription
Therapeutic area:
POLYENES
Product summary:
Active ingredient group (AIG) number: 0105864001; AHFS:
Authorization status:
APPROVED
Authorization date:
2018-06-08
Summary of Product characteristics
MONOGRAPHIE DE PRODUIT
PR
FUNGIZONE
MD
AMPHOTÉRICINE B POUR INJECTION, NORME MANUFACTURER
POUR PERFUSION INTRAVEINEUSE
50 MG/FIOLE
ANTIFONGIQUE
12 décembre 2019
Date de la révision :
N
o
de contrôle : 233219
Tel: 1-888-XEDITON
Ontario L5N 1W1
2000 Argentia Rd, Mississauga,
Xediton Pharmaceuticals Inc,
Distribué par
GmbH
MD
de La Société CHEPLAPHARM Arzneimittel
Ziegelhof 24, 17489 Greifswald, Germany
CHEPLAPHARM Arzneimittel GmbH
CLASSIFICATION THÉRAPEUTIQUE
......................................................................................
3
ACTIONS ET PHARMACOLOGIE
CLINIQUE............................................................................
3
INDICATIONS ET USAGE CLINIQUE
.......................................................................................
3
CONTRE-INDICATION
..............................................................................................................
5
MISES EN GARDE
....................................................................................................................
5
PRÉCAUTIONS
.........................................................................................................................
5
RÉACTIONS INDÉSIRABLES
...................................................................................................
7
SYMPTÔMES ET TRAITEMENT DU SURDOSAGE
................................................................. 9
POSOLOGIE ET ADMINISTRATION
.........................................................................................
9
RENSEIGNEMENTS PHARMACEUTIQUES
............................................................................13
PRÉSENTATION DES FORMES POSOLOGIQUES
................................................................14
MICROBIOLOGIE
.....................................................................................................................14
PHARMACOLOGIE
..................................................................................................................16
TOXICOLOGIE
.........
Read the complete document
